Safety and feasibility clinical trial of nucleus accumbens deep brain stimulation for treatment-refractory opioid use disorder.
Ali R Rezai, James J Mahoney, Manish Ranjan...
https://pubmed.ncbi.nlm.nih.gov/37329519/Actively Recruiting
Led by University of California, San Francisco · Updated on 2025-10-28
6
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are evaluating an individualized adaptive deep brain stimulation aDBS approach for people with severe Opioid Use Disorder OUD who have not responded to standard treatments. The study aims to determine if this personalized brain stimulation, guided by invasive brain mapping, is safe and can reduce craving and opioid use. The devices used are investigational and not yet approved by the FDA for OUD treatment. The study also seeks to better understand how OUD affects the brain. Participants will undergo three different treatment periods in a randomized order adaptive deep brain stimulation aDBS, continuous deep brain stimulation cDBS, and sham placebo stimulation. Each treatment period lasts four months. The sequence of these treatments varies among different participant groups to compare effects. The aDBS protocol is tailored to examine therapeutic outcomes based on individual brain activity. During the study, participants will be closely monitored for safety through adverse event tracking during brain mapping and stimulation phases. Brain mapping will occur over up to two weeks, while stimulation treatments continue for up to 16 months after device implantation. Researchers will assess opioid use, overall functioning, and therapy effects throughout. Participants must comply with study procedures and attend follow-ups, with support systems in place to help maintain engagement. Total study participation can last over a year, with continuous evaluation of safety and treatment impact.
CONDITIONS
Individualized Adaptive Deep Brain Stimulation in Opioid Use Disorder
C
Catherine Borror, BS
S
Sierra Brandts, BS
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University of California, San Francisco
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 2 weeks
Participants undergo implantation of the deep brain stimulation device and initial brain mapping with sEEG over up to 2 weeks.
Multiple visits during sEEG phase
Duration - 12 months
Participants receive three consecutive 4-month periods of adaptive deep brain stimulation (aDBS), continuous deep brain stimulation (cDBS), and sham stimulation in randomized order to assess therapeutic effects.
Visits as scheduled during each 4-month stimulation period
Duration - Up to 16 months from time of implantation
Participants are monitored for safety and treatment outcomes up to 16 months after device implantation.
Visits as scheduled for safety and outcome monitoring
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
TREATMENT
Number of Arms
3
Have more questions? Get in touch with our team for quick support
Ali R Rezai, James J Mahoney, Manish Ranjan...
https://pubmed.ncbi.nlm.nih.gov/37329519/J Kuhn, M Möller, J F Treppmann...
https://pubmed.ncbi.nlm.nih.gov/23337942/Hongyu Zhou, Jiwen Xu, Jiyao Jiang
https://pubmed.ncbi.nlm.nih.gov/21489407/Lei Chen, Nan Li, Shunnan Ge...
https://pubmed.ncbi.nlm.nih.gov/30245163/University of California, San Francisco
Lead Sponsor